Use caution with history of pancreatitis, gallbladder disease, or diabetic retinopathy, and stay hydrated to reduce acute kidney injury risk
49 Babenko AY, Savitskaya DA, Kononova YA, Trofimova AY, Simanenkova AV, Vasilyeva EY, et al
Retatrutide (also known as LY3437943) is an investigational medication developed by Eli Lilly that activates three key metabolic receptors : GLP-1 (glucagon-like peptide-1): reduces appetite and improves blood sugar control GIP (glucose-dependent insulinotropic polypeptide): enhances insulin response Glucagon receptor: increases energy expenditure and fat metabolism This triple-hormone weight loss drug approach creates a balanced effect, suppressing hunger and increasing calorie burn, something earlier GLP-1 medications couldnt fully achieve
The dose-response relationship favors IV delivery
JACC Cardiovasc Imaging 11:577585
CJC-1295 + Ipamorelin CJC-1295 and Ipamorelin are often paired because they help increase the bodys natural release of growth hormone